Lyell Immunopharma Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Lyell Immunopharma's estimated annual revenue is currently $10.1M per year.(i)
  • Lyell Immunopharma's estimated revenue per employee is $33,800
  • Lyell Immunopharma's current valuation is $1.5B. (January 2022)

Employee Data

  • Lyell Immunopharma has 300 Employees.(i)
  • Lyell Immunopharma grew their employee count by -13% last year.

Lyell Immunopharma's People

NameTitleEmail/Phone
1
VP, Process SciencesReveal Email/Phone
2
VP LegalReveal Email/Phone
3
VP FinanceReveal Email/Phone
4
Head Project Management OfficeReveal Email/Phone
5
SVP, Communications & Investor RelationsReveal Email/Phone
6
VP regulatory affairsReveal Email/Phone
7
VP ManufacturingReveal Email/Phone
8
VP BioinformaticsReveal Email/Phone
9
SVP, Clinical Development OperationsReveal Email/Phone
10
SVP, Human ResourcesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Lyell Immunopharma?

We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on CAR-Ts and solid tumors.

keywords:N/A

N/A

Total Funding

300

Number of Employees

$10.1M

Revenue (est)

-13%

Employee Growth %

$1.5B

Valuation

N/A

Accelerator

Lyell Immunopharma News

2022-04-13 - Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest ...

The Goldman Sachs Group cut their target price on shares of Lyell Immunopharma from $31.00 to $21.00 and set a “buy” rating on the stock in a...

2022-03-22 - Lyell Immunopharma Reports Fourth Quarter and Full Year ...

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company...

2022-03-22 - Form 3 Lyell Immunopharma, Inc. For: Mar 23 Filed by ...

Form 3 Lyell Immunopharma, Inc. For: Mar 23 Filed by: Albertson Tina M. March 29, 2022 5:08 PM. FORM 3, UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$69M31819%$743M
#2
$71.8M3315%$306M
#3
$127.9M37910%N/A
#4
$130.6M387N/AN/A
#5
$12.8M403-5%$59.3M